Track Revelation Biosciences's accounts payable ($830K) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Revelation Biosciences posts a accounts payable of $830K as of March 2026. That compares with $630K in the prior-year period — up 32.5% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, Revelation Biosciences's accounts payable was $630K. The latest reading is $830K — a 32.5% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.
Accounts Payable is one piece of Revelation Biosciences's financial statement story. At $830K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for REVB's accounts payable usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Revelation Biosciences's other metric pages and overview cover the third.